This narrative review highlights the association of dopamine with eating disorders, suggesting impacts on treatment strategies.
The prevalence of eating disorders (ED), such as anorexia, bulimia, and binge‐eating disorders, is on the rise, and it is imperative to explore the pathophysiological aspects and associations of these disorders to provide better and precise treatment. Dopamine is an essential hormone and a neurotransmitter involved in an array of processes and pathways. Disruption of any of the dopamine pathways can lead to diseases such as Parkinson's, Huntington's, schizophrenia, or anhedonia. The mesolimbic pathway of dopamine has a special association with the feeding behavior of a person, and disruption of this pathway has been shown to be associated with ED. In this article, we comprehensively assess the relation between dopamine and ED and discuss the clinical implications involving the pharmacological associations of drugs influencing dopamine levels and their impact on the treatment of ED.
No takes yet. Share an insight, caveat, or question.
Tharwani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: